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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The objectives are to systematically review the effect of intravenous iron or no iron in combination with erythropoiesis-stimulating
agents (ESAs) on the prevention or alleviation of anaemic cancer patients and to generate a clinically meaningful treatment ranking
according to their safety and efficacy.
B A C K G R O U N D
Description of the condition
A widely prevalent complication in patients suffering from can-
cer is the deficiency of haemoglobin-containing red blood cells
(RBCs), referred to as anaemia (Knight 2004). The prevalence
and incidence of anaemia in cancer patients is high and it is an
important contributor to morbidity and poor performance sta-
tus (Ludwig 2004). The reported age-adjusted incidence rate of
cancer in the USA in 2010 was 457.5 per 100,000 persons, with
the age-adjusted death rate of 171.8 per 100,000 persons per year
(Howlader 2014). TheEuropeanprospective survey found apreva-
lence of anaemia in cancer patients of 39.3%at enrolment, increas-
ing to 67% during the six months observation period (Ludwig
2004). Patients suffering from haematological malignancies fre-
quently experience anaemia. This frequency ranges from 30%
to 40% in patients diagnosed with Non-Hodgkin’s Lymphomas
(NHL) or Hodgkin’s lymphoma (HL), up to 70% of patients with
multiple myeloma, and higher in patients with myelodysplastic
syndrome (Garton 1995; Tonia 2012). The intensity of anaemia
has been classified, by the National Cancer Institute (NCI), based
on the following haemoglobin (Hb) values (Groopman 1999):
• grade 0, within normal limits, Hb values are 12.0 g/dL to
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16.0 g/dL for women and 14.0 g/dL to 18.0 g/dL for men;
• grade 1, mild (Hb 10 g/dL to normal limits);
• grade 2, moderate (Hb 8.0 g/dL to 10.0 g/dL);
• grade 3, serious/severe (Hb 6.5 g/dL to 8.0 g/dL); and
• grade 4, life-threatening (Hb less than 6.5 g/dL).
Anaemia of chronic disorders (ACD)
Due to an involvement of malignant bone marrow cells, the inci-
dence rate of patients with symptomatic anaemia at the stage solid
tumour diagnosis, prior to treatment, ranges from 31% to 50%.
Furthermore, patients in advanced stages of haematological malig-
nancies experience progressive anaemia with an incidence propor-
tion of higher than 50% (Knight 2004; Ludwig 2004; Link 2013).
With the exclusion of causes, such as iron or vitamin deficiencies,
occult bleeding or pure RBC anaemia, progressive anaemia can
be categorised as “anaemia of chronic disorders” (ACD). ACD
is characterised by a close interaction of malignant cells and the
patient’s immune system. The severity of symptoms of anaemia
varies among patients according to the progression of said disor-
der, including headaches, tachycardia, shortness of breath and pal-
pitation. Chronic anaemia on the other hand may result in severe
organ damage within the cardiovascular system, immune system
and central nervous system (Nissenson 1992; Ludwig 2001).
Chemotherapy-induced anaemia (CIA)
The percentage of cancer patients, developing anaemia as a result of
chemotherapy is estimated to be approximately 83% (Barrett-Lee
2006). CIA is most commonly reported in patients with gynae-
cological tumours, with a frequency of 81% to 88%, as well
as patients with lung carcinoma (77% to 83%) (Ludwig 2004).
CIAmaymanifest comparable tomild-to-moderate anaemia, with
symptoms including dyspnoea, fatigue and weakness. These re-
strictive symptoms may lead to a decrease in quality of life and
performance status of the patients (Littlewood 2001; Stasi 2003;
Mancuso 2006).
Radiotherapy-induced anaemia (RIA)
RIA is reported in 38% of all treated patients, with a repeating
pattern of patients with gynaecological tumours and lung carci-
noma showing the highest incidence proportion, with 54% and
51%, respectively. Moreover, the rate at which patients develop
anaemia due to a combination of radio- and chemotherapy is ap-
proximately 62% (Ludwig 2004).
Description of the intervention
Therapeutic alternatives are either treating the underlying cause or
providing supportive care throughRBC transfusions, recombinant
human erythropoiesis-stimulating agents (ESAs) or iron (Rodgers
2012). Studies have shown a correlation of serious thromboem-
bolic events and increased mortality of patients undergoing RBC
transfusions (Bohlius 2006; Khorana 2008; Mercadante 2009).
Erythropoiesis-stimulating agents (ESAs)
ESAs contain proteins, which in response to a hypoxic environ-
ment stimulate the production of RBCs within the bone marrow.
In the Cochrane review evaluating ESAs versus no ESAs in cancer
patients, Tonia and colleagues found that this interaction leads
to a significant reduction of RBC transfusions (risk ratio (RR)
0.65 (95% confidence interval (CI) 0.62 to 0.68)) needed for the
treatment of anaemic cancer patients and hence the potential to
an increase in quality of life (QoL) (Tonia 2012). Event though,
thought to be an effective treatment in cancer patients suffering
from chronic anaemia, ESAs have been shown to increase the risk
of venous thromboembolisms by up to 57% (Bennett 2008).The
risk ratio for thromboembolic complications was increased in pa-
tients receiving ESAs compared to controls (RR 1.52, 95% CI
1.34 to 1.74) (Tonia 2012). In addition, there is strong evidence
for increased mortality during active study period for patients re-
ceiving ESA (hazard ratio (HR) 1.17; 95% CI 1.06 to 1.29), and
some evidence that ESAs decrease overall survival (HR 1.05; 95%
CI 1.00 to 1.11) (Tonia 2012).Due to these findings, theNational
Comprehensive Cancer Network (NCCN) discourage the use of
ESAs, as a stand-alone treatment for anaemia in cancer patients
(NCCN 2016).
Iron supplements
Iron supplements have been proposed as an adjunct to ESAs for
the treatment of anaemic, as well as CIA/RIA patients. This is due
to the fact that patients treated with ESAs alone have shown to
produce iron-poor erythrocytes in the bone marrow, leading to a
functional iron deficiency (FID) (Eschbach 2005). Mhaskar and
colleagues show iron supplementation to have a positive effect on
the reduction in the risk for RBC transfusions (RR 0.74 (95%
CI 0.60 to 0.92)) and increased Hb levels (mean difference (MD)
0.48 (95% CI 0.10 to 0.86)) when administered with ESAs (
Mhaskar 2016). However, none of the eight included randomised
controlled (RCTs) trials reported overall survival (Mhaskar 2016).
Both oral and intravenous (IV) iron therapy, including low-molec-
ular weight iron dextran, iron sucrose and ferric gluconate, have
shown adverse effects, such as constipation, nausea, emesis and
diarrhoea (Fletes 2001; Mamula 2002; Chertow 2004; Chertow
2006). Intravenous iron might also lead to allergic reactions and
pseudoanaphylaxis (anaphylactoid reactions), causing an anaphy-
laxis, in approximately 68 per 10,000 patients (Wang 2015).
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ESAs plus iron supplements
Despite the research to determine the efficacy of iron supplement
adjunct to ESAs for the treatment of cancer patients with anaemia
and CIAs, the results are conflicting. Althought evidence has been
published, showing an increased response of ESAs, increased Hb
levels, greater haematopoietic response and improved health-re-
lated quality of life in patients being treated with ESAs and IV
iron (Bellet 2007; Hedenus 2007; Bastit 2008; Pedrazzoli 2008),
others have shown IV iron to have no essential impact on the
before-mentioned aspects in comparison to oral iron or placebo
(Steensma 2011). On the contrary, Tonia and colleagues pointed
out that only the subgroup of patients not receiving iron addition-
ally to ESAs had a statistically significant overall survival advan-
tage compared to those patients not receiving ESAs (Tonia 2012).
However, due to methodological constraints of meta-analyses of
RCTs, all the trials handling iron differently in the ESA-arm and
the no ESA-arm could not be analysed adequately.
How the intervention might work
ESAs contain an acidic glycoprotein-hormone, which facilitates
the production of erythrocytes in the bone marrow. While the
desired effect of an increase of Hb levels is achieved with the use
of ESAs, the treatment without iron supplements often results in
patients developing FID. FID is a result of ESAs reducing the
amount of circulating iron molecules, hence yielding iron-poor
erythrocytes in the bone marrow. Therefore adjuvant iron is used
to prevent the development of FID (Mhaskar 2016). Furthermore,
iron supplements may reduce the required ESA dose to obtain
desired Hb levels (Auerbach 2008).
Why it is important to do this review
Recommendations in current guidelines are inconsistent regard-
ing the usage of ESAs and iron, especially regarding IV iron. The
guidelines by the American Society of Hematology (ASH) and
the American Society of Clinical Oncology (ASCO) do not con-
sider the usage of IV iron as standard of care (Rizzo 2010). The
European Organisation for Research and Treatment of Cancer
(EORTC) (Bokemeyer 2007) guidelines found evidence for an
improved response to ESA with IV iron, but point out that the
doses and schedules for IV iron supplementation are not yet well
defined (Bokemeyer 2007). The guidelines by the European So-
ciety of Medical Oncology (ESMO) suggest additional iron to
ESAs for iron-deficient patients (Schrijvers 2010), and the Na-
tional Comprehensive Cancer Network (NCCN) guidelines con-
sider IV iron supplementation for absolute or functional iron de-
ficiency (Rodgers 2012).
In the Cochrane review evaluating ESAs versus no ESAs in cancer
patients, Tonia and colleagues found strong evidence for increased
mortality for patients receiving ESAs. However, in the subgroup
analysis evaluating iron supplementation, they reported a statis-
tically significant survival advantage in the subgroup with no ex-
plicit statement on iron supplementation or no iron given for pa-
tients receiving ESA (Tonia 2012). As they evaluated only pair-
wise comparisons, the treatment arms of studies handling iron dif-
ferently in both study arms could not sufficiently be considered in
the subgroup analyses. Network meta-analyses can overcome this
disadvantage of pair-wise comparisons.
In order to provide the highest level of evidence for treatment de-
cisions in cancer patients, we will conduct a network meta-analy-
sis that summarises the direct and indirect evidence for different
preventive and therapeutic strategies for CIA in cancer patients.
O B J E C T I V E S
The objectives are to systematically review the effect of intravenous
iron or no iron in combination with erythropoiesis-stimulating
agents (ESAs) on the prevention or alleviation of anaemic cancer
patients and to generate a clinically meaningful treatment ranking
according to their safety and efficacy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider only randomised controlled trials (RCTs), in
which randomisationwas conducted according to ESA and/or iron
status. We will include both full-text and abstract publications if
sufficient information is available on study design, characteristics
of participants and interventions provided.
Types of participants
We will include trials on patients of any age with solid cancer and/
or haematological malignancy undergoing chemotherapy, radio-
therapy or no anti-cancer therapy. We will apply no gender or
ethnicity restrictions. We will only include studies in which par-
ticipants are anaemic or at risk for anaemia from chemotherapy,
radiotherapy or combination therapy, or the underlyingmalignant
disease.
Studies including patients suffering from anaemia as a result of
surgery will be excluded, as well as patients suffering from anaemia
due to haemolysis.
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Types of interventions
Included trials will address one or multiple of the following inter-
ventions:
• ESA + IV iron;
• ESA + oral iron;
• ESA + no iron;
• ESA + iron unclear;
• ESA + iron, unclear application;
• no ESA + IV iron;
• no ESA + oral iron;
• no ESA + iron unclear;
• no ESA + iron, application unclear;
• no treatment - defined as baseline therapy excluding the
addition of ESAs, or iron supplementation; and
• placebo.
All interventions will be compared to each other using a network
meta-analysis (Figure 1).We assume that any patient thatmeets the
inclusion criteria is, in principle, equally likely to be randomised to
any of the eligible interventions. We plan to group interventions
by merging doses according to the product characteristics.
Figure 1.
Types of outcome measures
We will estimate the relative ranking of the competing interven-
tions according to the following outcomes:
• on-study mortality (deaths occurring up to 30 days after the
active study period);
• number of red blood cell (RBC) transfusions;
• haematological response (proportion of participants with an
increase in haemoglobin (Hb) level of 2 g/dL or more, or
increase in haematocrit of six percentage points or more,
unrelated to transfusion);
• overall survival (longest follow-up available); and
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• adverse events (AEs).
Primary outcomes
As the primary outcome we will evaluate on-study mortality. This
is due to the quantitatively low number of studies reporting long
follow-up time periods. Long-term follow-up is prone to be less
precisewhen it comes to recording the number of deaths, hence on-
studymortality ismore appropriate as a primary outcomemeasure.
Secondary outcomes
We will analyse the following outcomes as secondary outcomes:
• number of red blood cell (RBC) transfusions;
• haematological (Hb) response;
• overall survival; and
• AEs.
Search methods for identification of studies
We will adapt search strategies as suggested in Chapter Six of
the Cochrane Handbook for Systematic Reviews of Interventions
(Lefebvre 2011). We will apply no language restrictions to reduce
language bias. Only trials that compare at least two of the inter-
ventions are eligible. We will search for all possible comparisons
formed by the interventions of interest.
Electronic searches
We will search the following databases and sources:
• databases of medical literature:
◦ MEDLINE (Ovid) (1950 to present) (Appendix 1);
◦ the Cochrane Central Register of Controlled Trials
(CENTRAL) (the Cochrane Library, latest issue) (Appendix 2);
• conference proceedings of annual meetings of the following
societies for abstracts, if not included in CENTRAL (2010 to
present):
◦ American Society of Hematology;
◦ American Society of Clinical Oncology;
◦ European Hematology Association;
• databases of ongoing trials:
◦ register of controlled trials: www.controlled-trials.com;
◦ EU clinical trials register: www.clinicaltrialsregister.eu/
ctr-search/search;
◦ clinicaltrials.gov: www.clinicaltrials.gov; and
• databases and websites of relevant institutions, and
organisations (e.g. pharmaceutical industries).
Searching other resources
• Handsearching of references:
◦ references of all identified trials and relevant review
articles; current treatment guidelines as further literature.
We will use the following sources to identify the studies for this
network meta-analysis:
• previous Cochrane reviews on the effect of ESAs on cancer
patients with anaemia, as well as patients with CIA (Tonia 2012;
Mhaskar 2016); and
• reference lists of other systematic reviews and meta-analyses.
Data collection and analysis
Selection of studies
Two review authors will independently screen results of search
strategies for eligibility for this review by reading all abstracts. In
cases of disagreement, we will obtain the full-text publication. If
no consensus can be reached, we will ask a third review author
(Higgins 2011a).
We will document the process of study selection in a flow chart,
as recommended by the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement (Moher 2009),
showing total numbers of retrieved references and numbers of
included and excluded studies.
Data extraction and management
Two review authors will independently extract data according to
Chapter Seven of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a). We will contact authors of individ-
ual studies to ask for additional information, if required. We will
use a standardised data extraction form containing the following
items:
• general information:
◦ author, title, source, publication date, country,
language, duplicate publications;
• quality assessment:
◦ allocation concealment, blinding (participants,
personnel, outcome assessors), incomplete outcome data,
selective outcome reporting, other sources of bias;
• study characteristics:
◦ trial design, aims, setting and dates, source of
participants, inclusion/exclusion criteria, subgroup analysis,
treatment cross-overs, compliance with assigned treatment,
length of follow-up;
• participant characteristics:
◦ patient’s age, gender, number of participants recruited/
allocated/evaluated, participants lost to follow-up, type of
treatment, underlying disease, newly diagnosed or relapsed;
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• interventions:
◦ placebo use, ESA-dose, iron-dose, dosing regimen,
duration, route of administration, RBC transfusion trigger, co-
medications with dose, co-treatment, route and timing; and
• outcomes:
◦ on-study mortality, haematological response, overall
survival, AEs, number of RBC transfusions.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the following criteria, as outlined in Chapter Eight
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b):
• sequence generation;
• allocation concealment;
• blinding (participants, personnel, outcome assessors);
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We will make a judgement for each criterion, using one of the
following categories:
• ’Low risk’: if the criterion is adequately fulfilled in the study
(i.e. the study is at low risk of bias for the given criterion);
• ’High risk’: if the criterion is not fulfilled in the study (i.e.
the study is at high risk of bias for the given criterion); and
• ’Unclear’: if the study report does not provide sufficient
information to allow a clear judgement, or if risk of bias is
unknown for one of the criteria listed above.
Measures of treatment effect
We will use intention-to-treat data. For binary outcomes, we will
use risk ratios (RRs) with 95% confidence intervals (CIs) as the
measure of treatment effect. For time-to-event outcomes, we will
use hazard ratios (HRs) and their 95% CIs. Data will be extracted
from publications according to Parmar 1998 and Tierney 2007.
Wewill calculate continuous outcomes asmean differences (MDs)
with 95% CIs. We do not expect continuous outcomes assessed
with different instruments, so standardised MD is not required.
Relative treatment ranking
We will obtain a treatment hierarchy using P-scores (Rücker
2015). P-scores allow ranking treatments on a continuous 0 to 1
scale in a frequentist network meta-analysis.
Unit of analysis issues
Studies with multiple treatment groups
As recommended in Chapter 16.5.4 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), for studies
with multiple treatment groups, we will combine arms as long as
they can be regarded as subtypes of the same intervention.
When arms can not be pooled this way, we will compare each arm
with the common comparator separately. For pair-wise meta-anal-
ysis, we will split the ‘shared’ group into two or more groups with
smaller sample size, and include two or more (reasonably indepen-
dent) comparisons. For this purpose, for dichotomous outcomes,
both the number of events and the total number of patients will
be divided up, and for continuous outcomes, the total number of
participants will be divided up with unchanged means and stan-
dard deviations. For networkmeta-analysis, instead of subdividing
the common comparator, we will use an approach that accounts
for the within-study correlation between the effect sizes by re-
weighting all comparisons of each multi-arm study (Rücker 2012,
Rücker 2014).
Dealing with missing data
As suggested in Chapter 16 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011), we will take the fol-
lowing steps to deal with missing data.
Whenever possible, we will contact the original investigators to
request relevant missing data. If the number of patients evaluated
for a given outcome is not reported, we will use the number of pa-
tients randomised per treatment arm as denominator. If only per-
centages but no absolute number of events are reported for binary
outcomes, we will calculate numerators using percentages. If esti-
mates for mean and standard deviations are missing, we will cal-
culate these statistics from reported data whenever possible, using
approaches described in Chapter 7.7 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a). If standard
deviations are missing and we are not able to calculate them from
reported data, we will calculate values according to a validated
imputation method (Furukwa 2006). If data are not reported in
a numerical but graphical format, we will estimate missing data
from figures. We will perform sensitivity analyses to assess how
sensitive results are to imputing data in some way. We will address
in the Discussion section the potential impact of missing data on
findings of the review.
Assessment of heterogeneity
Pair-wise meta-analyses
For each direct comparison, we will visually inspect the forest
plots as well as Cochran’s Q based on a Chi2 statistic and the I2
statistic in order to detect the presence of heterogeneity. We will
interpret I2 values according to Chapter 9.5.2 of the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011).We
will use the P value of the Chi2 test only for describing the extent
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of heterogeneity and not for determining statistical significance.
In addition, we will report 2, the between-study variance in
random-effects meta-analysis.
Network meta-analysis
A very important pre-supposition for using network meta-analysis
is to make sure that the network is consistent, meaning that di-
rect and indirect evidence on the same comparisons agree. Incon-
sistency can be caused by incomparable inclusion and exclusion
criteria of the trials in the network.
We will evaluate the assumption of transitivity epidemiologically
by comparing the distribution of the potential effect modifiers
across the different pair-wise comparisons. For each set of studies,
grouped by treatment comparison, we will create a table of impor-
tant clinical and methodological characteristics. We will visually
inspect the similarity of these factors, including the inclusion and
exclusion criteria of every trial in the network.
To evaluate the presence of inconsistency locally, we will use the
Bucher method for single loops of evidence (Bucher 1997), as de-
scribed for example in Dias 2013. For each closed loop, we will
calculate the difference between direct and indirect evidence to-
gether with its 95% confidence interval. We will use loop-specific
z-tests to infer about the presence of inconsistency in each loop.
We will use graphical representation of estimates of inconsistency
together with 95% confidence intervals and will report the per-
centage of inconsistent loops in the network. It should be noted
that in a network of evidence there may be many loops and with
multiple testing there is an increased likelihood that we might find
an inconsistent loop by chance. Therefore, we will be cautious
deriving conclusions from this approach.
To evaluate the presence of inconsistency in the entire network,
we will give the generalised heterogeneity statistic Qtotal and the
generalised I2 statistic, as described in Schwarzer 2015.Wewill use
the decomp.design command in the R package netmeta (R 2014,
netmeta 2016) for decomposition of the heterogeneity statistic
into a Q statistic for assessing the heterogeneity between studies
with the same design and a Q statistic for assessing the design’s in-
consistency to identify the amount of heterogeneity/inconsistency
within as well as between designs. Furthermore, we will create a
net heat plot (Krahn 2013), a graphical tool for locating incon-
sistency in network meta-analysis, using the command netheat in
the R package netmeta. We will give Qtotal and its components
as well as net heat plots based on fixed-effect and random-effects
models to identify differences between these approaches. For ran-
dom-effects models, we will report 2.
If we find substantive heterogeneity and/or inconsistency, we will
explore possible sources by performing pre-specified sensitivity
and subgroup analyses (see below). In addition, we will review the
evidence base, reconsider inclusion criteria as well as discuss the
potential role of unmeasured effect modifiers to identify further
sources.
Assessment of reporting biases
In pair-wise comparisons with at least 10 trials, we will examine
the presence of small-study effects graphically by generating funnel
plots. We will use linear regression tests (Egger 1997) to test for
funnel plot asymmetry. A P value less than 0.1 will be considered
significant for this test (Sterne 2011).Wewill examine the presence
of small-study effects for the primary outcome only.
Data synthesis
Methods for direct treatment comparisons
Wewill perform analyses according to recommendations provided
in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2011), and we will use the statistical software
of Cochrane - Review Manager (RevMan) 2014 - for analysis. If
applicable, we will use R (R 2014) for additional analyses that can
not be done with RevMan.
If adequate, we will perform standard pair-wise meta-analyses us-
ing a random-effects model for every treatment comparison with
at least two studies. We will calculate corresponding 95% confi-
dence intervals for all analyses, and will present the results graph-
ically using forest plots. When trials are clinically too heteroge-
nous to be combined (e.g. various types of diseases), we will per-
form only subgroup analyses without calculating an overall esti-
mate. We will create a ’Summary of findings’ table on absolute
risks in each group according to the Grades of Recommenda-
tion, Assessment, Development and Evaluation (GRADE) system
(GRADEpro; Schuenemann 2011; Puhan 2014), and in this table,
we will summarise the evidence on on-study mortality, number of
RBC transfusions, haematological response, overall survival and
AEs.
Methods for indirect and mixed comparisons
Should the data be considered sufficiently similar to be combined,
we will perform a network meta-analysis using the frequentist
weighted least squared approach described by Rücker 2012. We
will use a random-effects model, taking into account the corre-
lated treatment effects in multi-arm studies. We will assume a
common estimate for the heterogeneity variance across the differ-
ent comparisons. To evaluate the extent to which treatments are
connected, we will give a network plot for our primary and sec-
ondary outcomes. For each comparison, we will give the estimated
treatment effect along with its 95% confidence interval. We will
graphically present the results using forest plots, with placebo as
reference. We will use the R package netmeta (R 2014, netmeta
2016) for statistical analyses.
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Subgroup analysis and investigation of heterogeneity
The following subgroup analysis will be conducted, if appropriate:
• type of iron (iron dextran, ferrous gluconate, ferrous
sulphate, etc.);
• route of iron administration (IV versus oral);
• type of ESA (epoetin versus darbepoetin);
• type of anti-cancer therapy (chemotherapy, radiotherapy,
no treatment);
• cancer type; and
• duration of follow-up.
Sensitivity analysis
To test the robustness of the results, we will conduct fixed-effect
pair-wise and network meta-analyses. We will report the estimates
of the fixed-effect only if they show a difference to the random-
effectsmodel.We will explore the influence of quality components
with regard to low and high risk of bias.
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Appendix 1. MEDLINE search strategies
MEDLINE/Ovid (included Epub Ahead of Print, In-Process & Other Non-Indexed Citations)
Search Strategy:
# Searches
1 exp ANEMIA/dt, th [Drug Therapy, Therapy]
2 anaemia$.tw,kf,ot.
3 anemia$.tw,kf,ot.
4 ((anemi$ or anaemi$) adj3 cancer).tw,kf,ot.
5 or/1-4
6 ANEMIA, IRON-DEFICIENCY/
7 Iron/
8 IRON COMPOUNDS/
9 exp FERRIC COMPOUNDS/
10 FERROUS COMPOUNDS/
11 iron$.tw,kf,ot.
12 iron$.sh.
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(Continued)
13 ferri$.tw,kf,ot.
14 (ferro$ adj2 (compound$ or compund$)).tw,kf,ot.
15 hemosider$.tw,kf,ot.
16 sideros$.tw,kf,ot.
17 transferrin$.tw,kf,ot.
18 or/6-17
19 5 or 18
20 exp NEOPLASMS BY HISTOLOGIC TYPE/
21 exp NEOPLASMS BY SITE/
22 neoplas$.tw,kf,ot.
23 tumo?r$.tw,kf,ot.
24 (Krebs$ or cancer$).tw,kf,ot.
25 malignan$.tw,kf,ot.
26 (carcino$ or karzino$).tw,kf,ot.
27 karzinom$.tw,kf,ot.
28 sarcom$.tw,kf,ot.
29 leuk#?m$.tw,kf,ot.
30 lymphom$.tw,kf,ot.
31 melano$.tw,kf,ot.
32 metastas$.tw,kf,ot.
33 (mesothelio$ or mesotelio$).tw,kf,ot.
34 carcinomatos$.tw,kf,ot.
35 (gliom$ or glioblastom$).tw,kf,ot.
36 osteo?sarcom$.tw,kf,ot.
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(Continued)
37 (blastom$ or neuroblastom$).tw,kf,ot.
38 oncol$.tw.
39 myelodysplas$.tw.
40 or/20-39
41 chemotherapy.mp.
42 exp ANTINEOPLASTIC AGENTS/
43 REMISSION INDUCTION/
44 exp ANTINEOPLASTIC PROTOCOLS/
45 ((consolidat$ or induct$ or maintenance or conditioning$) and (therap$ or treat$ or regimen$ or patient$)).tw,kf,ot
46 ((anticancer$ or cancer$) adj2 (therap$ or treat$)).tw,kf,ot
47 (remission$ adj2 therap$).tw,kf,ot.
48 (remission$ adj2 induction$).tw,kf,ot.
49 (chemotherap$ or chemo-therap$).tw,kf,ot.
50 (Antineoplast$ or anti-neoplast$).tw,kf,ot.
51 ((cytosta$ or cytotox$) adj2 (therap$ or treat$ or regimen$)).tw,kf,ot
52 or/41-51
53 randomized controlled trial.pt.
54 controlled clinical trial.pt.
55 randomi?ed.ab.
56 placebo.ab.
57 clinical trials as topic.sh.
58 randomly.ab.
59 trial.ti.
60 or/53-59
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(Continued)
61 humans.sh.
62 60 and 61
63 40 or 52
64 19 and 63
65 64 and 62
66 limit 65 to ed=20151116-20170107
MEDLINE/Ovid Search Strategy:
# Searches
1 exp ERYTHROPOIETIN/
2 erythropoietin.mp.
3 erythropoiesis.mp.
4 exp EPOETIN ALFA/
5 epoetin.mp.
6 epo.mp.
7 epoetin alfa.mp.
8 epoetin beta.mp.
9 eprex.mp.
10 neorecormon.mp.
11 aranesp.mp.
12 procrit.mp.
13 recombinant erythropoietin.mp.
14 darbepoetin alfa.mp.
15 darbepoetin.mp.
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(Continued)
16 RECEPTORS, ERYTHROPOIETIN/
17 CERA.mp.
18 epoetin theta.mp.
19 epoetin zeta.mp.
20 silapo*.tw,kf,nm,ot.
21 retacrit*.tw,kf,nm,ot.
22 biopoin*.tw,kf,nm,ot.
23 eporatio*.tw,kf,nm,ot.
24 or/1-23
25 anaemia.mp.
26 anemia.mp.
27 (anemi* adj3 cancer).mp.
28 (anaemi* adj3 cancer).mp.
29 or/25-28
30 ANEMIA, IRON-DEFICIENCY/
31 IRON/
32 IRON COMPOUNDS/
33 iron*.sh.
34 iron*.tw,kf,ot.
35 ferri*.tw,kf,ot.
36 (ferro* adj2 (compound* or compund*)).tw,kf,ot.
37 hemosider*.tw,kf,ot.
38 sideros*.tw,kf,ot.
39 transferrin*.tw,kf,ot.
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(Continued)
40 or/30-39
41 exp NEOPLASMS/
42 malignan*.mp.
43 cancer*.mp.
44 oncolog*.tw.
45 myelodysplas*.tw.
46 chemotherapy.mp.
47 tumo?r*.mp.
48 carcinom*.mp.
49 or/41-48
50 exp ANTINEOPLASTIC AGENTS/
51 REMISSION INDUCTION/
52 exp ANTINEOPLASTIC PROTOCOLS/
53 ((consolidat* or induct* or maintenance or conditioning*) and (therap* or treat* or regimen* or patient*)).tw,kf,ot
54 ((anticancer* or cancer*) adj2 (therap* or treat*)).tw,kf,ot
55 (remission* adj2 therap*).tw,kf,ot.
56 (remission* adj2 induction*).tw,kf,ot.
57 (chemotherap* or chemo-therap*).tw,kf,ot.
58 (Antineoplast* or anti-neoplast*).tw,kf,ot.
59 ((cytosta* or cytotox*) adj2 (therap* or treat* or regimen*)).tw,kf,ot
60 or/50-59
61 randomized controlled trial.pt.
62 controlled clinical trial.pt.
63 randomi?ed.ab.
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(Continued)
64 placebo.ab.
65 drug therapy.fs.
66 randomly.ab.
67 trial.ab.
68 groups.ab.
69 or/61-68
70 humans.sh.
71 69 and 70
72 60 and 71
73 24 and 29 and 40
74 73 and 49
75 73 and 60
76 74 or 75
77 76 and 71
Appendix 2. CENTRAL search strategies
Cochrane Central Register of Controlled Trials
#1 MESH DESCRIPTOR ANEMIA EXPLODE ALL TREES
#2 anaemia:TI,AB,KY
#3 anemia:TI,AB,KY
#4 (((anemi* or anaemi*) adj3 cancer)):TI,AB,KY
#5 #1 OR #2 OR #3 OR #4
#6 MESH DESCRIPTOR Anemia, Iron-Deficiency EXPLODE ALL TREES
#7 MESH DESCRIPTOR Iron EXPLODE ALL TREES
#8 MESH DESCRIPTOR Iron Compounds EXPLODE ALL TREES
#9 MESH DESCRIPTOR Ferric Compounds EXPLODE ALL TREES
#10 MESH DESCRIPTOR Ferrous Compounds EXPLODE ALL TREES
#11 iron*:TI,AB,KY
#12 ferri*:TI,AB,KY
#13 ((ferro* adj2 (compound* or compund*))):TI,AB,KY
#14 hemosider*:TI,AB,KY
#15 sideros*:TI,AB,KY
#16 transferrin*:TI,AB,KY
#17 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
#18 #5 OR #17
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#19 MESH DESCRIPTOR NEOPLASMS BY HISTOLOGIC TYPE EXPLODE ALL TREES
#20 MESH DESCRIPTOR NEOPLASMS BY SITE EXPLODE ALL TREES
#21 neoplas*:TI,AB,KY
#22 ((tumor* OR tumour*)):TI,AB,KY
#23 ((Krebs* or cancer*)):TI,AB,KY
#24 malignan*:TI,AB,KY
#25 ((carcino* or karzino*)):TI,AB,KY
#26 karzinom*:TI,AB,KY
#27 sarcom*:TI,AB,KY
#28 (leukem* OR leukaemi* OR leucem*):TI,AB,KY
#29 lymphom*:TI,AB,KY
#30 melano*:TI,AB,KY
#31 metastas*:TI,AB,KY
#32 (mesothelio* OR mesotelio*):TI,AB,KY
#33 carcinomatos*:TI,AB,KY
#34 ((gliom* or glioblastom*)):TI,AB,KY
#35 osteo*sarcom*:TI,AB,KY
#36 ((blastom* or neuroblastom*)):TI,AB,KY
#37 oncol*:TI,AB,KY
#38 myelodysplas*:TI,AB,KY
#39 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33
OR #34 OR #35 OR #36 OR #37 OR #38
#40 MESH DESCRIPTOR Antineoplastic Agents EXPLODE ALL TREES
#41 MESH DESCRIPTOR Remission Induction EXPLODE ALL TREES
#42 MESH DESCRIPTOR antineoplastic protocols EXPLODE ALL TREES
#43 ((((consolidat* or induct* or maintenance or conditioning*) and (therap* or treat* or regimen* or patient*)))):TI,AB,KY
#44 ((((anticancer* or cancer*) adj2 (therap* or treat*)))):TI,AB,KY
#45 (((remission* adj2 therap*))):TI,AB,KY
#46 (((remission* adj2 induction*))):TI,AB,KY
#47 (((chemotherap* or chemo-therap*))):TI,AB,KY
#48 (((Antineoplast* or anti-neoplast*))):TI,AB,KY
#49 ((((cytosta* or cytotox*) adj2 (therap* or treat* or regimen*)))):TI,AB,KY
#50 #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49
#51 #39 or #50
#52 #18 and #51
Cochrane Central Register of Controlled Trials Search Strategy
ID Search
#1 MeSH descriptor: [Erythropoietin] explode all trees
#2 erythropoietin
#3 erythropoiesis
#4 MeSH descriptor: [Epoetin Alfa] explode all trees
#5 epoetin
#6 epo
#7 epoetin alfa
#8 epoetin beta
#9 eprex
#10 neorecormon
#11 aranesp
#12 procrit
#13 recombinant erythropoietin
#14 darbepoetin alfa
#15 darbepoetin
#16 MeSH descriptor: [Receptors, Erythropoietin] explode all trees
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N O T E S
Some passages in the protocol and review, especially in the methods part, are from the standard template of CHMG
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